[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2018008469A - Metodos y dispositivos para tratar trastornos oculares posteriores con aflibercept y otros productos biologicos. - Google Patents

Metodos y dispositivos para tratar trastornos oculares posteriores con aflibercept y otros productos biologicos.

Info

Publication number
MX2018008469A
MX2018008469A MX2018008469A MX2018008469A MX2018008469A MX 2018008469 A MX2018008469 A MX 2018008469A MX 2018008469 A MX2018008469 A MX 2018008469A MX 2018008469 A MX2018008469 A MX 2018008469A MX 2018008469 A MX2018008469 A MX 2018008469A
Authority
MX
Mexico
Prior art keywords
devices
end portion
methods
medicament container
disorderswith
Prior art date
Application number
MX2018008469A
Other languages
English (en)
Inventor
Patel Samirkumar
Original Assignee
Clearside Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clearside Biomedical Inc filed Critical Clearside Biomedical Inc
Publication of MX2018008469A publication Critical patent/MX2018008469A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

La presente invención se refiere a métodos y dispositivos para tratar la AMD húmeda, CNV, AMD húmeda asociada con CNV y/o AMD húmeda asociada con RVO en un sujeto humano que lo necesite. En ciertos aspectos, los dispositivos que sé proporcionan en la presente incluyen un recipiente de medicamento que define un lumen configurado para contener un medicamento, una porción del extremo distante del recipiente de medicamento que incluye una porción de acoplamiento configurada para acoplarse de manera desmontable a un conjunto de aguja, una porción del extremo próximo del recipiente de medicamento que incluye una pestaña y un hombro longitudinal; un conjunto de pistón que incluye una porción del extremo distante dispuesta de manera móvil dentro del lumen del recipiente de medicamento; y un asa acoplada a una porción del extremo próximo del conjunto de pistón.
MX2018008469A 2016-01-08 2017-01-09 Metodos y dispositivos para tratar trastornos oculares posteriores con aflibercept y otros productos biologicos. MX2018008469A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662276543P 2016-01-08 2016-01-08
US201662324708P 2016-04-19 2016-04-19
PCT/US2017/012757 WO2017120601A1 (en) 2016-01-08 2017-01-09 Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics

Publications (1)

Publication Number Publication Date
MX2018008469A true MX2018008469A (es) 2018-11-09

Family

ID=59274052

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008469A MX2018008469A (es) 2016-01-08 2017-01-09 Metodos y dispositivos para tratar trastornos oculares posteriores con aflibercept y otros productos biologicos.

Country Status (9)

Country Link
EP (1) EP3400014A1 (es)
JP (1) JP2019501200A (es)
KR (1) KR20180101488A (es)
CN (1) CN108778330A (es)
AU (1) AU2017206114A1 (es)
BR (1) BR112018013805A2 (es)
CA (1) CA3010862A1 (es)
MX (1) MX2018008469A (es)
WO (1) WO2017120601A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
CN106214321B (zh) 2010-10-15 2018-08-28 科尼尔赛德生物医学公司 用于进入眼睛的装置
MX2015005839A (es) 2012-11-08 2015-12-17 Clearside Biomedical Inc Metodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
BR112015027762A2 (pt) 2013-05-03 2017-08-29 Clearside Biomedical Inc Aparelho e métodos para injeção ocular
WO2014197317A1 (en) 2013-06-03 2014-12-11 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
US10273298B2 (en) 2013-07-23 2019-04-30 Novaliq Gmbh Stabilized antibody compositions
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
US11066465B2 (en) 2015-12-30 2021-07-20 Kodiak Sciences Inc. Antibodies and conjugates thereof
CA3019426A1 (en) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
EP3452165A1 (en) 2016-05-02 2019-03-13 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
WO2018031913A1 (en) 2016-08-12 2018-02-15 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
US12090294B2 (en) 2017-05-02 2024-09-17 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
KR20200060456A (ko) * 2017-09-27 2020-05-29 리젠엑스바이오 인크. 완전-인간 번역후 변형된 항-VEGF Fab를 이용한 안구 질환의 치료
WO2019125798A1 (en) * 2017-12-20 2019-06-27 Angex Pharmaceutical, Inc. Carbamate and urea compounds as multikinase inhibitors
CN108030783A (zh) * 2017-12-27 2018-05-15 广东众生药业股份有限公司 乐伐替尼在制备防治黄斑变性的药物中的用途
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
CN112739323A (zh) * 2018-05-10 2021-04-30 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
CN110693886B (zh) * 2018-07-09 2022-12-06 天津医科大学 防治脑海绵状血管畸形病变的药物
CN113710228A (zh) * 2019-02-13 2021-11-26 诺瓦利克有限责任公司 用于治疗眼部新生血管形成的组合物和方法
KR20200101160A (ko) * 2019-02-19 2020-08-27 전남대학교산학협력단 리보세라닙을 포함하는 안구 신생혈관 억제용 약학 조성물 및 이를 이용한 안구 신생혈관 억제 방법
JP2022521851A (ja) * 2019-04-03 2022-04-12 レジェンクスバイオ インコーポレーテッド 眼の病態に対する遺伝子療法
CN110522909B (zh) * 2019-09-30 2024-02-20 安徽省立医院 一种协同增强抗her2阳性肿瘤效果的药物组合
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
JP2023500385A (ja) * 2019-11-11 2023-01-05 シーストーン・ファーマシューティカルズ・（スージョウ）・カンパニー・リミテッド 医薬組合せ物およびその使用
CN115697333A (zh) * 2020-02-19 2023-02-03 科尼尔赛德生物医学公司 包含阿西替尼的组合物和治疗眼部疾病的方法
WO2021257193A1 (en) * 2020-06-15 2021-12-23 Opko Pharmaceuticals, Llc Triamcinolone acetonide-loaded liposomes topical ophthalmic formulations as primary therapy for macular edema secondary to branch retinal vein occlusion
EP4185318A1 (en) * 2021-05-17 2023-05-31 Regeneron Pharmaceuticals, Inc. Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
CN113546176B (zh) * 2021-06-30 2024-03-15 南通大学 一种特异性用于抑制眼内血管新生药物合成方法
CN118356501A (zh) * 2023-01-19 2024-07-19 百奥泰生物制药股份有限公司 一种复方制剂及其应用
WO2024167694A2 (en) * 2023-02-06 2024-08-15 Celularity Inc. Placental extracellular matrices for ocular delivery of ophthalmic therapeutic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013029713A2 (pt) * 2011-05-27 2016-09-06 Novartis Ag método de tratamento de distúrbios da visão
CA2865132A1 (en) * 2012-02-22 2013-08-29 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
MX2015005839A (es) * 2012-11-08 2015-12-17 Clearside Biomedical Inc Metodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
EP3082761A2 (en) * 2013-12-20 2016-10-26 Emory University Formulations and methods for targeted ocular delivery of therapeutic agents
US20180042765A1 (en) * 2014-06-17 2018-02-15 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorders

Also Published As

Publication number Publication date
KR20180101488A (ko) 2018-09-12
BR112018013805A2 (pt) 2018-12-11
AU2017206114A1 (en) 2018-08-02
CN108778330A (zh) 2018-11-09
JP2019501200A (ja) 2019-01-17
CA3010862A1 (en) 2017-07-13
WO2017120601A1 (en) 2017-07-13
EP3400014A1 (en) 2018-11-14

Similar Documents

Publication Publication Date Title
MX2018008469A (es) Metodos y dispositivos para tratar trastornos oculares posteriores con aflibercept y otros productos biologicos.
MX2016016836A (es) Metodos y dispositivos para tratar trastornos oculares posteriores.
PH12014502792A1 (en) Soft tip cannula
MX2017000920A (es) Dispositivos magneticos para anastomosis y metodos de entrega.
EP2456363A4 (en) INTRODUCTION INSTRUMENT FOR PROSTHETIC VALVE
MX2016016070A (es) Introductor y guia de cateter con aguja tangencial subretinal.
MX2020008980A (es) Dispositivo de administracion de farmacos.
EP4324414A3 (en) Devices and methods for treating the skin using a rollerball or a wicking member
IN2015DN02530A (es)
MX2018012770A (es) Funda para sonda de oximetria portatil.
WO2015164839A3 (en) System and method for safety syringe
USD738490S1 (en) Prosthesis insertion bellow
WO2014127389A3 (en) Thrombectomy catheter
MX2019010386A (es) Jeringa de clip.
MX2017000609A (es) Dispositivo y metodo de entrega de implante ocular.
BR112015017366A8 (pt) dispositivo médico para facilitar a seleção de um implante de anuloplastia
GB2511375A (en) Deployment Catheter
MX2020011003A (es) Valvula para dilatador y ensamble de cubierta.
MX2017001673A (es) Prenda de compresion medica terapeutica y metodo.
MX2016004859A (es) Conector de cateter.
MY192494A (en) Vaginal composition and use thereof
CO6500125A1 (es) Suministro de curcumina por derivacion
WO2017079325A3 (en) Injection devices and systems and methods for using them
MX2015011418A (es) Tratamiento de enfermedades con nanofibras de poli-n-acetilglucosamina.
MX2017001555A (es) Dispositivo para insertar una canula de punta roma bajo la piel de un paciente.